Key Details
Price
$4.54Annual ROE
-154.91%Beta
1.89Events Calendar
Next earnings date:
Mar 21, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 01, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Cibus and Biographica to collaborate on identifying gene editing targets for Cibus' disease resistance trait development
Cibus, Inc. (NASDAQ:CBUS ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Carlo Broos - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Matthew Venezia - Alliance Global Partners Operator Good day, and welcome to the Cibus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
The greenhouse results represent an important success milestone in the development of its second-generation of HT2 edited Canola
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results on Thursday, November 7, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20% Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20%
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, has been named a finalist for the Euroseeds2024 InnovActor Award and will have its technology showcased on the InnovAction Stage at the Euroseeds2024 Congress. Cibus' presentation will be given by Dr. Jim Radtke (SVP Product Development) who was recently honored by the American Seed Trade Association (ASTA) with a Lifetime Achievement Award. The event will take place in Copenhagen, Denmark, October 13-16 with the winner named at the 2024 InnovActor Ceremony on October 15.
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, today announced that Peter Beetham, Co-Founder, President and Chief Operating Officer, will participate in a panel discussion titled “Sowing Solutions: Innovations in Climate-Resilient Seeds” at the Food+ Forum during the 79th session of the United Nations General Assembly (“UNGA”) in New York, NY, on Thursday, September 26, at 12:50 pm ET.
SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of an underwritten public offering of 3,000,000 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”) at a public offering price of $4.00 per share. The Company has granted the underwriters a 45-day option to purchase an additional 450,000 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the offering are to be sold by the Company.
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock in an underwritten public offering. Cibus also expects to grant to the underwriters of the offering a 45-day option to purchase up to an additional 15% of the shares of Class A common stock offered in the underwritten public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Certain existing institutional and accredited investors and Rory Riggs, Cibus' Chief Executive Officer, have indicated an interest in purchasing shares of Class A Common Stock in this offering. Because these indications of interest are not binding agreements or commitments to purchase, those certain existing investors and Mr. Riggs may elect not to purchase any shares in this offering, or the underwriters may elect not to sell any shares in this offering to those certain existing investors or Mr. Riggs.
Cibus, Inc. (NASDAQ:CBUS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Nick Anderson - ROTH Capital Matthew Venezia - Alliance Global Partners Austin Moeller - Canaccord Sameer Joshi - H.C. Wainwright Steve Byrne - Bank of America Operator I'd like to turn the conference over to Wade King, Chief Financial Officer.
FAQ
- What is the primary business of Cibus?
- What is the ticker symbol for Cibus?
- Does Cibus pay dividends?
- What sector is Cibus in?
- What industry is Cibus in?
- What country is Cibus based in?
- When did Cibus go public?
- Is Cibus in the S&P 500?
- Is Cibus in the NASDAQ 100?
- Is Cibus in the Dow Jones?
- When was Cibus's last earnings report?
- When does Cibus report earnings?
- Should I buy Cibus stock now?